• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    TeloVac Lancet Oncology Revised ...
    Size:
    617.8Kb
    Format:
    PDF
    Download
    Authors
    Middleton, G
    Silcocks, P
    Cox, T
    Valle, Juan W
    Wadsley, J
    Propper, D
    Coxon, F
    Ross, P
    Madhusudan, S
    Roques, T
    Cunningham, D
    Falk, S
    Wadd, N
    Harrison, M
    Corrie, Pippa
    Iveson, Tim
    Robinson, A
    McAdam, K
    Eatock, M
    Evans, J
    Archer, C
    Hickish, T
    Garcia-Alonso, A
    Nicolson, M
    Steward, W
    Anthoney, A
    Greenhalf, W
    Shaw, V
    Costello, E
    Naisbitt, D
    Rawcliffe, C
    Nanson, G
    Neoptolemos, J
    Show allShow less
    Affiliation
    University of Birmingham, Edgbaston, Birmingham, UK.
    Issue Date
    2014-07
    
    Metadata
    Show full item record
    Abstract
    We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.
    Citation
    Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet Oncol
    Journal
    The Lancet Oncology
    URI
    http://hdl.handle.net/10541/322604
    DOI
    10.1016/S1470-2045(14)70236-0
    PubMed ID
    24954781
    Type
    Article
    Language
    en
    ISSN
    1474-5488
    ae974a485f413a2113503eed53cd6c53
    10.1016/S1470-2045(14)70236-0
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    • Authors: Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T
    • Issue date: 2013 Apr
    • Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
    • Authors: Middleton G, Greenhalf W, Costello E, Shaw V, Cox T, Ghaneh P, Palmer DH, Neoptolemos JP
    • Issue date: 2016 Mar 1
    • Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.
    • Authors: Staff C, Mozaffari F, Frödin JE, Mellstedt H, Liljefors M
    • Issue date: 2014 Sep
    • Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    • Authors: Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators
    • Issue date: 2021 Feb
    • Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    • Authors: Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C
    • Issue date: 2017 May
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.